Report Detail
Global Acute Myeloid Leukemia Drugs Market Insights, Forecast to 2025
- RnM3447663 |
- 22 May, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
The global Acute Myeloid Leukemia Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Acute Myeloid Leukemia Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Acute Myeloid Leukemia Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acute Myeloid Leukemia Drugs in these regions.
This research report categorizes the global Acute Myeloid Leukemia Drugs market by top players/brands, region, type and end user. This report also studies the global Acute Myeloid Leukemia Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Market size by Product
DC regimen
AVD Regimen
VCD regimen
Market size by End User
Hospital
Clinic
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Acute Myeloid Leukemia Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Acute Myeloid Leukemia Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Acute Myeloid Leukemia Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Acute Myeloid Leukemia Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Acute Myeloid Leukemia Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acute Myeloid Leukemia Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Acute Myeloid Leukemia Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by Product
- 1.4.2 DC regimen
- 1.4.3 AVD Regimen
- 1.4.4 VCD regimen
- 1.5 Market by End User
- 1.5.1 Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Acute Myeloid Leukemia Drugs Market Size
- 2.1.1 Global Acute Myeloid Leukemia Drugs Revenue 2014-2025
- 2.1.2 Global Acute Myeloid Leukemia Drugs Sales 2014-2025
- 2.2 Acute Myeloid Leukemia Drugs Growth Rate by Regions
- 2.2.1 Global Acute Myeloid Leukemia Drugs Sales by Regions
- 2.2.2 Global Acute Myeloid Leukemia Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Acute Myeloid Leukemia Drugs Sales by Manufacturers
- 3.1.1 Acute Myeloid Leukemia Drugs Sales by Manufacturers
- 3.1.2 Acute Myeloid Leukemia Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Acute Myeloid Leukemia Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Acute Myeloid Leukemia Drugs Revenue by Manufacturers
- 3.2.1 Acute Myeloid Leukemia Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Acute Myeloid Leukemia Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Acute Myeloid Leukemia Drugs Price by Manufacturers
- 3.4 Acute Myeloid Leukemia Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Acute Myeloid Leukemia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Acute Myeloid Leukemia Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Acute Myeloid Leukemia Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Acute Myeloid Leukemia Drugs Sales by Product
- 4.2 Global Acute Myeloid Leukemia Drugs Revenue by Product
- 4.3 Acute Myeloid Leukemia Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Acute Myeloid Leukemia Drugs Breakdown Data by End User
6 North America
- 6.1 North America Acute Myeloid Leukemia Drugs by Countries
- 6.1.1 North America Acute Myeloid Leukemia Drugs Sales by Countries
- 6.1.2 North America Acute Myeloid Leukemia Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Acute Myeloid Leukemia Drugs by Product
- 6.3 North America Acute Myeloid Leukemia Drugs by End User
7 Europe
- 7.1 Europe Acute Myeloid Leukemia Drugs by Countries
- 7.1.1 Europe Acute Myeloid Leukemia Drugs Sales by Countries
- 7.1.2 Europe Acute Myeloid Leukemia Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Acute Myeloid Leukemia Drugs by Product
- 7.3 Europe Acute Myeloid Leukemia Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Acute Myeloid Leukemia Drugs by Countries
- 8.1.1 Asia Pacific Acute Myeloid Leukemia Drugs Sales by Countries
- 8.1.2 Asia Pacific Acute Myeloid Leukemia Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Acute Myeloid Leukemia Drugs by Product
- 8.3 Asia Pacific Acute Myeloid Leukemia Drugs by End User
9 Central & South America
- 9.1 Central & South America Acute Myeloid Leukemia Drugs by Countries
- 9.1.1 Central & South America Acute Myeloid Leukemia Drugs Sales by Countries
- 9.1.2 Central & South America Acute Myeloid Leukemia Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Acute Myeloid Leukemia Drugs by Product
- 9.3 Central & South America Acute Myeloid Leukemia Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Acute Myeloid Leukemia Drugs by Countries
- 10.1.1 Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Countries
- 10.1.2 Middle East and Africa Acute Myeloid Leukemia Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Acute Myeloid Leukemia Drugs by Product
- 10.3 Middle East and Africa Acute Myeloid Leukemia Drugs by End User
11 Company Profiles
- 11.1 Ambit Biosciences Corporation
- 11.1.1 Ambit Biosciences Corporation Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Products Offered
- 11.1.5 Ambit Biosciences Corporation Recent Development
- 11.2 Celgene Corporation
- 11.2.1 Celgene Corporation Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Celgene Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Celgene Corporation Acute Myeloid Leukemia Drugs Products Offered
- 11.2.5 Celgene Corporation Recent Development
- 11.3 Cephalon
- 11.3.1 Cephalon Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Cephalon Acute Myeloid Leukemia Drugs Products Offered
- 11.3.5 Cephalon Recent Development
- 11.4 Clavis Pharma
- 11.4.1 Clavis Pharma Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Clavis Pharma Acute Myeloid Leukemia Drugs Products Offered
- 11.4.5 Clavis Pharma Recent Development
- 11.5 Eisai
- 11.5.1 Eisai Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Eisai Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Eisai Acute Myeloid Leukemia Drugs Products Offered
- 11.5.5 Eisai Recent Development
- 11.6 Genzyme Corporation
- 11.6.1 Genzyme Corporation Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Products Offered
- 11.6.5 Genzyme Corporation Recent Development
- 11.7 Sunesis Pharmaceuticals
- 11.7.1 Sunesis Pharmaceuticals Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Products Offered
- 11.7.5 Sunesis Pharmaceuticals Recent Development
12 Future Forecast
- 12.1 Acute Myeloid Leukemia Drugs Market Forecast by Regions
- 12.1.1 Global Acute Myeloid Leukemia Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Acute Myeloid Leukemia Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Acute Myeloid Leukemia Drugs Market Forecast by Product
- 12.2.1 Global Acute Myeloid Leukemia Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Acute Myeloid Leukemia Drugs Revenue Forecast by Product 2019-2025
- 12.3 Acute Myeloid Leukemia Drugs Market Forecast by End User
- 12.4 North America Acute Myeloid Leukemia Drugs Forecast
- 12.5 Europe Acute Myeloid Leukemia Drugs Forecast
- 12.6 Asia Pacific Acute Myeloid Leukemia Drugs Forecast
- 12.7 Central & South America Acute Myeloid Leukemia Drugs Forecast
- 12.8 Middle East and Africa Acute Myeloid Leukemia Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Acute Myeloid Leukemia Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Acute Myeloid Leukemia Drugs . Industry analysis & Market Report on Acute Myeloid Leukemia Drugs is a syndicated market report, published as Global Acute Myeloid Leukemia Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Acute Myeloid Leukemia Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
